NCT02306629 - Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the Blood | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Systemic Lupus Erythematosus

Interventions

BIOLOGICAL

Epratuzumab sc

Active substance: Epratuzumab, Pharmaceutical form: Solution for injection, Route of Administration: Subcutaneous,

BIOLOGICAL

Epratuzumab iv

Active substance: Epratuzumab, Pharmaceutical form: Solution for Infusion, Route of Administration: Intravenous,

Trial Locations (1)

01, London